Stryker Strikes Again, Buys HyperBranch Medical Technology
Stryker is continuing its buying spree with the purchase of HyperBranch Medical Technology. The orthopedics giant announced it will pay $220m in an all-cash deal to buy the maker of Adherus, a hydrogel that helps dural repair.
You may also be interested in...
Device/Diagnostics Quarterly Dealmaking Statistics, Q4 2018
Device fundraising in the fourth quarter totaled $1.5bn, a 42% decrease from Q3's $2.6bn. Q4 M&A activity reached $8.6bn. Q4 diagnostics financings brought in $1.2bn (a 32% increase over Q3) and M&As totaled $1.3bn (the second-highest quarter of the year).
2018 Earnings Spotlight: Stryker And Nuvasive Lead The Ortho Pack In 2018
Reported sales and earnings from the big publicly traded orthopedics device companies showed mostly slow growth in 2018, but NuVasive and Stryker reported high single-digit growth while, Smith & Nephew grew in the low single-digits, fueling reports that Smith & Nephew may try to buy NuVasive.
Q3 Earnings Spotlight: Ortho Firms Show Mixed Results Against US Pricing Pressure
Reported sales and earnings from the publicly traded orthopedics device companies showed mix results during the third quarter of 2018. NuVasive was the star performer in the group while, on the other end of the spectrum, Stryker continued to show strong growth across most its businesses, while Johnson & Johnson's orthopedic device revenue was near flat.</p>